Predictive value of cystic fibrosis transmembrane conductance regulator (CFTR) in the diagnosis of gastric cancer

Abstract

Predictive value of cystic brosis transmembrane conductance regulator (CFTR) in the diagnosis of gastric cancer Abstract Purpose: Gastric cancer is associated with poor prognosis. e high mortality rate of gastric cancer is mainly attributed to late detection, so diagnosis and treatment are crucial to decreasing mortality. e purpose of this study was to examine the predictive accuracy and discriminative ability of cystic brosis transmembrane conductance regulator (CFTR) in gastric cancer patients, in addition to the classical cancer tumor biomarkers carbohydrate antigen 199 (CA199) and carcinoembryonic antigen (CEA).Methods: e study was performed on 78 serum samples from gastric cancer patients and 88 serum samples from healthy adults. Serum levels of CFTR, CA199, CEA and CHN were determined by enzyme-linked immunosorbent assay (ELISA)Results: Spearman's coe cient analysis showed that, in some cases, CFTR was strongly correlated with CA199 and that CFTR levels increased with age. Kruskal-Wallis testing indicated concentrations of CFTR and CA199 had statistically signi cant association with stage. Logistic regression showed that CFTR and CA199 independently predicted gastric cancer. Receiver operating characteristics (ROC) showed that combinations of CFTR, CA199, and CEA yielded the best ROC curve, with an AUC of 0.875.Conclusions: e results of this study indicate that the serum CFTR has a broad application prospects for detection of GC.

The efficacy and safety of targeted therapy with or without chemotherapy in advanced gastric cancer treatment: a network meta-analysis of well-designed randomized controlled trials

“…GLOBOCAN showed gastric cancer to be the fifth most common malignant tumor, with the third highest mortality in 2012 [1]. The high mortality stems from the considerable proportion of patients already presenting late-stage tumors at diagnosis [2]. Therefore, gastric cancer treatment mainly focuses on advanced stages.…”

High CFTR expression in philadelphia chromosome-positive acute leukemia protects and maintains continuous activation of BCR-ABL and related signaling pathways in combination with PP2A

“…Recent studies have provided credible evidence that CFTR is not only an anion channel protein but also acts as a regulator that interacts with other proteins through its PDZ domain to regulate their function [10, 11]. In recent years, an enormous amount of research has shown that aberrant expression or mutation of CFTR is involved in the incidence and development of gastric cancer, colon cancer, lung cancer, breast cancer, prostate cancer, cervical cancer, ovarian cancer and other tumors [12–16]. CFTR alterations differ among tumor types: in some cases, CFTR acts as a tumor suppressor gene (e.g., colon cancer and prostate cancer), whereas in others, it acts as an oncogene (e.g.,cervical cancer and ovarian cancer).…”

Emerging role of cystic fibrosis transmembrane conductance regulator - an epithelial chloride channel in gastrointestinal cancers

“…In their study, the expression of CFTR and the interaction between CFTR and afadin were linked to epithelial-mesenchymal transition (EMT), an important process during tumor metastasis, indicating that functional CFTR may act as a tumor suppressor, while the deficiency of CFTR would facilitate tumor progression in colon cancer [48] . The involvement of CFTR deficiency was also studied in other gastrointestinal malignancies such as gastric cancer [49] . It is reported that serum CFTR is significantly associated with a cancer biomarker, carbohydrate antigen 199 (CA199), and it is significantly associated with gastric cancer staging.…”

“…It is reported that serum CFTR is significantly associated with a cancer biomarker, carbohydrate antigen 199 (CA199), and it is significantly associated with gastric cancer staging. In addition, the combination of CFTR and CA199 yields a higher receiver operating characteristic (ROC) curve, which is used in the diagnosis of gastric cancer [49] . Although this research did not discuss the association between CFTR and gastric cancer, it has provided a potential biomarker for the diagnosis of not only gastric cancer but also other types of cancer.…”